1. The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy.
The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. Hamsters were immunized intramuscularly with 1 × 1010 PFU of Ad and inoculated with HPD-1NR cells one month later. Meanwhile, another group of naïve animals were also inoculated with HPD-1NR cells. The tumor-bearing hamsters were treated with 5 × 108 PFU of Ad5 (arrow) and 4F11 or control antibody as they were treated in Fig. 1. A, Sera and tumor tissue were harvested on the indicated days, and the levels of anti-Ad5 antibody were measured by ELISA. ConIg, control antibodies. B, Tumor tissues were harvested at the indicated times, and viral loads (left) and genome (right) in tumor were determined by TICD50 on JH-293 cells and the quantitative PCR assay, respectively. C, Tumor sizes were measured twice weekly. Error bars, mean ± SDs from 7 to 8 animals per group. Statistical analysis was conducted using two-way ANOVA test on time points after viral therapy. ***, P < 0.001; ns, not significant. Data are representative of two independent experiments.
Xiaozhu Li et al. Clin Cancer Res 2017;23:
©2017 by American Association for Cancer Research